Aliso Viejo, Calif. — Valeant Pharmaceuticals International, based here, has entered into an agreement with Spear Pharmaceuticals, Fort Myers, Fla., for the rights to commercialize Refissa (tretinoin cream, USP [emollient] 0.05 percent), a prescription topical cream used to treat fine wrinkles and irregular pigmentation due to sun damage, PR Newswire-FirstCall reports.
Valeant will pay Spear $12 million up front, and the companies will share net profits. Valeant will book sales and use its dermatology sales force to promote Refissa to dermatologists nationwide.
0 comments
Hide comments
